How new modalities against CD20 stack up at ASCO

Adicet’s Phase I data update at ASCO adds to the evidence that new modalities and alternative targets may help build on the efficacy of marketed CD19 CAR Ts. 

In a presentation at the American Society of Clinical Oncology meeting in Chicago on Monday, Adicet Bio Inc. (NASDAQ:ACET) reported that ADI-001, an allogeneic γδ CAR T cell targeting CD20, led to an objective response rate (ORR) and complete responses (CR) of 75% in eight patients with relapsed or refractory B cell non-Hodgkin lymphoma (NHL)...